Riptide Bioscience, Inc. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Bacterial keratitis, due to its potential to cause ir
Riptide Bioscience, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $222,179
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION (provided by applicant): Bacterial keratitis, due to its potential to cause irreversible blindness, requires prompt intervention. In the United States there are approximately 30,000 patients annually, with contact lens wear being the prime riskfactor. Bacterial keratitis i presently treated with antibiotics however innovation in antimicrobial agents and treatment is needed due to the rapid emergence of bacterial resistance and resilience due to biofilm formation. Designed host defense peptides(dHDPs) are derived from naturally occurring HDPs which are ubiquitous in nature and provide the first line of defense against invading pathogens. Aero-Dap LLC has developed novel dHDPs with potent antibacterial activity which may also promote wound healing while concurrently reducing scarring and inflammation and thereby prevent potential blindness in patients with bacterial keratitis. In this proposal, the in vitro cytotoxicity and anti-inflammatory effects of the peptides will be evaluated on cornea